Research To Practice | Oncology Videos

Featuring a slide presentation and related discussion from Dr Adam Brufsky, including the following topics: Targeted therapies for HER2-expressing breast cancer (0:00) Rationale for targeting HER2-low breast cancer (6:51) Recent data with T-DXd in advanced HER2-low breast cancer (12:57) CME information and select publications

Featuring an interview with Dr Adam Brufsky, including the following topics: Trastuzumab deruxtecan (T-DXd) for HER2-low breast cancer; recently presented findings from the DESTINY-BREAST04 trial (0:00) Impact of heterogeneous disease on the detection of HER2-low expression in patients with breast cancer (7:48) Case: A woman with low-volume, asymptomatic and nonvisceral ER-positive, HER2-low breast cancer (13:16) Case: A woman with high-volume, symptomatic and visceral HER2-low breast cancer; treating ER-negative, HER2-low disease (18:44) Toxicities associated with T-DXd (25:25) Ongoing trials evaluating T-DXd in earlier lines of therapy (31:28) CME information and select publications

Featuring perspectives from Drs Justin Gainor, Corey Langer, Luis Paz‑Ares, Heather Wakelee, Jared Weiss and Helena Yu, including the following topics: Introduction (0:00) Incorporation of immunotherapeutic strategies into the management of nonmetastatic non-small cell lung cancer (NSCLC) — Heather Wakelee, MD (3:18) Contemporary treatment for localized and metastatic NSCLC with EGFR mutations — Helena Yu, MD (33:46) Research advances shaping the current and future treatment of metastatic NSCLC with ALK rearrangements, ROS1 rearrangements or RET fusions — Justin F Gainor, MD (58:03) Targeting alterations in MET, HER2, KRAS and other oncogenes in NSCLC — Jared Weiss, MD (1:19:24) Current and future management of metastatic NSCLC without a targetable tumor mutation — Corey J Langer, MD (1:42:57) Current treatment paradigm for small cell lung cancer — Luis Paz-Ares, MD, PhD (2:07:58) CME information and select publications

Featuring a slide presentation and related discussion from Dr Loretta Nastoupil, including the following topics: Current and emerging therapies for patients with follicular lymphoma (FL) (0:00) CAR (chimeric antigen receptor) T-cell therapy for patients with FL (10:34) Efficacy and tolerability of bispecific antibodies for patients with FL (19:6) CME information and select publications

Featuring an interview with Dr Loretta Nastoupil, including the following topics: Impact of COVID-19 on the management of follicular lymphoma (FL) (0:00) Case: A woman in her late 50s with Grade IIIA symptomatic FL (3:48) Case: A man in his early 70s with low-grade FL and asymptomatic adenopathy 6 years after a complete response (8:21) Case: A patient with heavily pretreated relapsed/refractory FL who received copanlisib followed by CAR (chimeric antigen receptor) T-cell therapy (14:56) Case: A woman in her early 50s with refractory FL who received mosunetuzumab (18:06) Novel treatment strategies for FL and considerations for the future (23:28) CME information and select publications

Featuring perspectives from Drs Yohann Loriot, Elizabeth Plimack and Jonathan Rosenberg, including the following topics: Introduction (0:00) Current and Future Management of Localized Urothelial Bladder Cancer (UBC) (2:59) First-Line Treatment for Patients with Metastatic UBC (mUBC) (28:29) Later-Line Therapeutic Options for Patients with mUBC: Novel Investigational Strategies (47:08) CME information and select publications

Featuring perspectives from Drs Ian Flinn, Brian Hill, John Leonard, Matthew Lunning, Laurie Sehn and Mitchell Smith, including the following topics: Introduction (0:00) Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) — Ian W Flinn, MD, PhD (3:07) Relapsed/Refractory CLL; Novel Investigational Strategies — Mitchell R Smith, MD, PhD (32:31) Treatment for Follicular Lymphoma — John P Leonard, MD (57:24) Management of Mantle Cell Lymphoma — Matthew Lunning, DO (1:21:22) Caring for Patients with Diffuse Large B-Cell Lymphoma — Laurie H Sehn, MD, MPH (1:44:40) Chimeric Antigen Receptor T-Cell Therapy — Brian T Hill, MD, PhD (2:10:26) CME information and select publications

Featuring perspectives from Drs Javier Cortés, Matthew Goetz, Erika Hamilton, Ian Krop, Hope Rugo and Sara Tolaney, including the following topics: Introduction (0:00) Optimizing the Management of ER-Positive Localized Breast Cancer — Matthew P Goetz, MD (7:50) New and Novel Treatment Strategies for Localized Triple-Negative Breast Cancer (TNBC) — Erika Hamilton, MD (38:35) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Ian E Krop, MD, PhD (56:03) Evolving Clinical Decision-Making for Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Javier Cortés, MD, PhD (1:18:47) Selection and Sequencing of Therapy for ER-Positive, HER2-Negative mBC — Hope S Rugo, MD (1:40:41) Recent Advances in the Care of Patients with Metastatic TNBC — Sara M Tolaney, MD, MPH (2:11:40) CME information and select publications

Featuring perspectives from Drs Tanios Bekaii-Saab, Kristen Ciombor, Eileen O'Reilly, Philip Philip, John Strickler and Prof Eric Van Cutsem, including the following topics: Introduction (0:00) Integration of targeted therapy and immunotherapy into the management of metastatic colorectal cancer — Kristen K Ciombor, MD, MSCI (3:15) Other considerations in the management of early and advanced colorectal cancer — John Strickler, MD (33:15) Current and future treatment paradigm for gastroesophageal cancers — Eric Van Cutsem, MD, PhD (55:26) Selection and sequencing of therapy for advanced hepatocellular carcinoma — Philip A Philip, MD, PhD, FRCP (1:23:00) Novel treatment strategies for advanced biliary tract cancers — Tanios Bekaii-Saab, MD (1:50:31) CME information and select publications

Featuring perspectives from Ms Paula Anastasia, Dr Robert Coleman, Dr David O'Malley and Ms Jaclyn Shaver, including the following topics: Introduction (0:00) Management of Endometrial Cancer (5:32) Treatment for Cervical Cancer (45:31) COVID-19: Considerations in Cervical and Endometrial Cancer (1:22:34) Oncology 2032 Crystal Ball (1:27:43) CME information and select publications